Wolverine + GHK-Cu (GLOW) Stack
BPC-157 + TB-500 + GHK-Cu broader-healing trio
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The three-peptide combination has never been tested in humans, and no published study examines whether the components add anything to one another or interfere. Evidence exists only piecewise and is uneven. BPC-157 rests almost entirely on rodent work from a single Croatian research group, extensive in volume but thin in independent replication and without a completed controlled human trial. TB-500 is weaker still, because the consumer product is a fragment sold against data generated on full-length thymosin beta-4, which did reach human trials for eye and skin wounds through RegeneRx without producing an approved product. GHK-Cu is the strongest of the three and the most narrowly supported, with genuine controlled data for topical cosmetic and wound applications and a large mechanistic literature led by Loren Pickart, none of it establishing benefit from systemic injection. What people report is uncontrolled and unblinded, in a setting where injury recovery improves with time anyway. Anyone claiming the stack has been validated is describing marketing rather than published evidence.
- FDA
- Not FDA-approved as a stack. BPC-157 and TB-500 are unapproved drugs; BPC-157 was placed in compounding Category 2 in 2023-2024. GHK-Cu is permitted in topical cosmetics, but injectable GHK-Cu is not an approved drug and falls under the same compounding scrutiny.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
High uncertainty, same core cautions as the two-peptide stack plus copper exposure. Not FDA-approved as a stack; BPC-157 and TB-500 are research-grade with unregulated purity and dosing. GHK-Cu is reasonably supported only for topical use; injectable GHK-Cu adds the question of how much copper enters the body, and copper overload can be harmful. Human safety data for the three together are absent. Banned in sport (BPC-157, TB-500). Long-term effects unknown.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Wolverine + GHK-Cu (GLOW) Stack. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
This variant adds GHK-Cu to the Wolverine pairing. GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper, a small peptide that occurs naturally in human plasma, saliva, and urine and that carries copper, a trace mineral used in tissue repair. People add it hoping to extend healing beyond tendon and muscle toward skin, collagen, and overall tissue regeneration; some sellers brand the three-peptide combination 'GLOW.' BPC-157 (Body Protection Compound 157) and TB-500 (a Thymosin Beta-4 related fragment) carry the soft-tissue claims, while GHK-Cu carries skin and collagen claims. GHK-Cu has more support than the other two, but mainly for topical (on-the-skin) wound and cosmetic use, not injection. The combined three-peptide stack has no human trials, and no single person is credited with creating it; it is a community and clinic assemblage, not a tested medical regimen.
broad healing
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
None of the three is an approved drug for injection in the United States, the European Union, the United Kingdom or Australia. FDA placed BPC-157 in the 503A Category 2 bulk substances list, effectively closing lawful compounding, and thymosin beta-4 related products sit in the same unapproved territory. GHK-Cu is a permitted cosmetic ingredient worldwide as copper tripeptide-1, which is a different regulatory question from injecting it. WADA prohibits BPC-157 and thymosin beta-4 analogues, so any athlete under testing is exposed. Material generally arrives as research-only lyophilised powder from unverified suppliers, with documented problems of misidentity, endotoxin and inaccurate fill. Copper adds a specific unknown, since repeated parenteral copper loading has no established safe ceiling and is not tracked by users.
What people get wrong
Often saidMyth: Adding GHK-Cu makes the stack 'complete' and proven.
ActuallyReality: The trio has no human trials; GHK-Cu's evidence is mainly topical, not injected, and not for this combination.
Often saidMyth: Copper peptide is automatically safe because it's 'natural.'
ActuallyReality: GHK-Cu occurs naturally, but injecting extra copper is not the same as natural plasma levels, and excess copper can be toxic.
Often saidMyth: 'GLOW' is a regulated branded medicine.
ActuallyReality: 'GLOW' is a marketing name used by sellers, not an FDA-approved product.
Who profits, and who pushes back
Westlake Dermatology
GHK-Cu's documented benefits are largely from topical use; injectable claims outrun the evidence (trend review).
American Journal of Sports Medicine systematic review
Human efficacy data for BPC-157 remain limited to a single qualifying study (2025).
USADA / WADA
BPC-157 and TB-500 are prohibited at all times under S0; their safety is not established.
Peptide dosing-protocol and clinic sites (e.g. GLOW stack guides)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Promote the trio under names like 'GLOW'; commercial interest.
Telehealth peptide and concierge med clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Bundle the three peptides as a premium recovery package.
Skincare and longevity influencers
Often enthusiastic about topical copper peptides; may carry affiliate links.
Biohacker forums
Believer-driven; assembled the variant from the base Wolverine stack.
Where the research comes from
Most of the published research on this comes from one place. 54% of it is from North America. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| North America | 54% |
| Europe | 21% |
| Asia-Pacific | 15% |
| Latin America | 6% |
| Other | 4% |
Research published from: USA.
How we got here
Each of the three parts arrived by a different road. BPC-157 comes out of Predrag Sikiric's group at the University of Zagreb, which from the early 1990s onward published a long run of rodent work on a fragment said to derive from a gastric protein. TB-500 circulates as a synthetic fragment marketed against the profile of thymosin beta-4, the full protein that RegeneRx Biopharmaceuticals carried into human trials for corneal and dermal wounds; the injectable sold to consumers is not that clinical material. GHK-Cu is the best documented of the three, described in human plasma by Loren Pickart during doctoral work at the University of California in the early 1970s and developed by him for decades afterward, which is why it reached cosmetic chemistry long before it reached bodybuilding forums. The trio itself was assembled by sellers and compounding-adjacent clinics rather than by any investigator, and the GLOW label spread through peptide vendor catalogues, Reddit peptide communities and longevity clinic menus during the late 2010s and early 2020s. Nobody has claimed authorship, and no published protocol defines it.
This is a derivative of the Wolverine Stack, adding GHK-Cu. GHK-Cu was first described in human plasma by researcher Loren Pickart, whose work in the 1970s onward established its copper-binding and tissue-repair properties; that lineage is well documented. The combination of GHK-Cu with BPC-157 and TB-500, however, comes from the peptide-selling and biohacking community, sometimes marketed as 'GLOW.' No individual is credited with assembling the trio, and the combined protocol is not independently validated. The 'Wolverine' portion of the name remains a community pop-culture reference of uncertain origin.
- 1970s-1980sLoren Pickart characterizes GHK and its copper complex GHK-Cu in human plasma.
- 1990sBPC-157 isolated at University of Zagreb.
- 2000s-2010sGHK-Cu becomes common in topical skincare; injectable peptide markets grow.
- 2010sThree-peptide variants circulate in biohacker and clinic settings; 'GLOW' branding appears.
- 2023-2024FDA Category 2 action affects BPC-157 and injectable peptide compounding.
- 2026Regulatory status of several peptides, including injectable GHK-Cu, under active reconsideration.
At a glance
- GHK-Cu
- copper-binding peptide found naturally in human plasma
- Added for
- skin, collagen, and broader tissue repair
- Sometimes branded
- 'GLOW' stack by peptide sellers
- Human trial of the trio
- none
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Wolverine + GHK-Cu (GLOW) Stack. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
FDA placed BPC-157 in Category 2 of the 503A bulk drug substances list, citing significant safety risks, which restricts lawful pharmacy compounding.
BPC-157 and thymosin beta-4 analogues are prohibited at all times for athletes under the World Anti-Doping Code.
US anti-doping guidance warns athletes that BPC-157 and similar research peptides are banned and sold without quality control.
GHK and GHK-Cu occur naturally in human plasma and act on skin remodelling and collagen pathways, with the literature reviewed by its original describer.
Pickart and Margolina, BioMed Research International (PubMed)
The BPC-157 evidence base is dominated by rodent studies from one research group, with human data lacking.
Sikiric et al., peer-reviewed pharmacology reviews indexed in PubMed
Thymosin beta-4 was investigated in registered human trials for corneal and dermal wound healing, none of which produced an approved product, and those trials used the full protein rather than the TB-500 fragment sold to consumers.
Copper tripeptide-1 is an accepted topical cosmetic ingredient, a status that does not extend to injectable use.
European Commission CosIng cosmetic ingredient database
No registered study evaluates BPC-157, TB-500 and GHK-Cu administered together in humans.